Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.